Free shipping on all orders over $ 500


Cat. No. M21293
BCPyr  Structure
Size Price Availability
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BCPyr is a new candidate BTK degradation agent (DC50 = 800 nM).

Chemical Information
Molecular Weight 1082.20
Formula C58H65F2N11O8
CAS Number 2669844-82-8
Solubility (25°C) N/A
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Boxing Zhu, et al. J Chem Phys. Radiative cooling rates of substituted PAH ions

[2] Mai Su, et al. Sci Total Environ. Levels, profiles and potential human health risks of brominated and parent polycyclic aromatic hydrocarbons in soils around three different types of industrial areas in China

[3] Jing Zheng, et al. Environ Sci Technol. Marine and Anthropogenic Bromopyrroles Alter Cellular Ca2+ Dynamics of Murine Cortical Neuronal Networks by Targeting the Ryanodine Receptor and Sarco/Endoplasmic Reticulum Ca2+-ATPase

[4] Ranran Liu, et al. Environ Int. Field study of PAHs with their derivatives emitted from e-waste dismantling processes and their comprehensive human exposure implications

[5] Matthew D Hall, et al. J Struct Biol. The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours

Related BTK Products

BMS-986143 is a potent, reversible inhibitor of tyrosine kinase (BTK), which has been successfully targeted by a number of irreversible tumor compounds.


The reversible BTK kinase inhibitor BIIB091 is a highly selective phase I clinical candidate compound for multiple sclerosis.


TAK-020 is a highly selective oral covalent BTK inhibitor with a promising safety and tolerability profile for both hematologic malignancies and autoimmune diseases.

BTK inhibitor 1 (Compound 27)

BTK inhibitor 1 (compound 27) is an inhibitor of BTK with an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM.


WYE-175837 is a BTK inhibitor

Abmole Inhibitor Catalog

Keywords: BCPyr supplier, BTK, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.